News for Amgen Inc. (AMGN.BA)

On CNBC's “Halftime Report Final Trades,” Brian Belski of BMO Capital Markets named Take-Two Interactive Software, Inc. TTWO as his final trade. On the ear...

On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview at CNBC and expressed that the tech sector could be heading into a period of major volatility.

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023. In 2023, the healthcare industry made up 17.6% of the US economy, an increase of 17.4% from 2022. The growth of Medicare and private […]

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.

Stocks sold off sharply after Federal Reserve Chair Jerome Powell gave his opinion on what tariffs mean for inflation and the next rate move by policymakers.

\nRegulatory News:\n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) today announced it will propose to its Annual Genera

\nAmgen is a top holding, representing 8.10% of the fund's total assets.Strong market positioning with a diverse portfolio of biologics and biosimilars.Risks inc

**media[594564]**

UBS has revised its price target for biotechnology firm Amgen (AMGN), increasing it slightly from $315 to $319. Despite this adjustment, the financial services

Sandoz (SDZNY) has initiated an antitrust lawsuit against Amgen (AMGN) in the US, accusing the latter of unlawfully maintaining its dominant market position wit

**media[593935]**

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.

President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries.

**media[589793]**

**media[589629]**

Looking into the current session, Amgen Inc. AMGN shares are trading at $289.09, after a 1.80% decrease. Over the past month, the stock fell by 9.34%, but over ...

Summary: Amgen (AMGN) has increased its dividend by 6% to $2.38 per share, yielding approximately 3%, showcasing robust financial health despite higher cost

Summary Amgen Inc (AMGN) announced on April 3, 2025, that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for a